Immune Resolution After Staphylococcus Aureus Bacteremia

NCT01879761 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 102

Last updated 2025-08-14

No results posted yet for this study

Summary

The purpose of this study is to determine how monocyte HLA-DR and other markers of immune function change with time in patients with and without prior immune dysfunction who survive sepsis from Staphylococcus aureus bacteremia.

We hypothesize that patients with prior immune dysfunction will have greater reductions in HLA-DR and other markers of immune function after an episode of sepsis than people who do not have prior immune dysfunction.

Conditions

  • Immune Response To Sepsis
  • Staphylococcus Aureus Infection

Sponsors & Collaborators

  • University of Chicago

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-06-30
Primary Completion
2026-06-30
Completion
2026-06-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01879761 on ClinicalTrials.gov